Galderma Laboratories, L.P. has announced that the US Food and Drug Administration (FDA) has approved Mirvaso® (brimonidine) topical gel, 0.33%

This content is restricted to site members. If you are an existing user, please log in. New users may register below.

New User Registration
 
 
 
 
 
 
 
 
 
* Please indicate that you agree to the Terms of Service
*Required field